Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7816396 | MERZ PHARMS | Method for increasing the bioavailability of glycopyrrolate |
Aug, 2023
(2 months from now) | |
US7638552 | MERZ PHARMS | Method for increasing the bioavailability of glycopyrrolate |
Aug, 2023
(2 months from now) |
Market Authorisation Date: 28 July, 2010
Treatment: Reduce chronic severe drooling (i.e., sialorrhea) in patients with neurologic conditions associated with problem drooling
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7316067 | SUNOVION RESP | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step |
Sep, 2022
(8 months ago) | |
US8511581 | SUNOVION RESP | Fluid droplet production apparatus and method |
Nov, 2023
(5 months from now) | |
US7458372 | SUNOVION RESP | Inhalation therapy device |
Nov, 2024
(1 year, 5 months from now) | |
US7931212 | SUNOVION RESP | Fluid droplet production apparatus and method |
Nov, 2025
(2 years from now) | |
US11278683 | SUNOVION RESP | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Aug, 2026
(3 years from now) | |
US9265900 | SUNOVION RESP | Disposable ampoule for an aerosol generating device |
Dec, 2028
(5 years from now) | |
US10940110 | SUNOVION RESP | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations |
Feb, 2029
(5 years from now) | |
US9789270 | SUNOVION RESP | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Oct, 2030
(7 years from now) | |
US9168556 | SUNOVION RESP | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer |
Sep, 2032
(9 years from now) | |
US9604018 | SUNOVION RESP | Aerosol therapy device |
May, 2033
(9 years from now) | |
US10376661 | SUNOVION RESP | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element |
Sep, 2035
(12 years from now) | |
US10688518 | SUNOVION RESP | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator |
Nov, 2036
(13 years from now) | |
US10744277 | SUNOVION RESP | Aerosol delivery device and method of operating the aerosol delivery device |
Dec, 2036
(13 years from now) |
Market Authorisation Date: 05 December, 2017
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd); A method of using an aerosol delivery device to aerosolize glycopyrrolate for the ...
Dosage: SOLUTION;INHALATION
26
European Union
23
United States
8
Germany
8
Spain
7
Japan
6
Canada
5
Australia
3
China
2
Russia
2
Austria
2
Brazil
2
United Kingdom
1
New Zealand
1
Hong Kong
1
Mexico
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(5 years from now) |
Market Authorisation Date: 29 October, 2015
Treatment: NA
Dosage: POWDER;INHALATION
15
United States
12
United Kingdom
9
European Union
8
Japan
6
China
5
Canada
5
Australia
3
Spain
3
Russia
3
Brazil
3
Norway
3
New Zealand
2
Hong Kong
2
Austria
2
Denmark
2
Poland
2
Singapore
2
Korea, Republic of
2
Cyprus
2
Portugal
2
South Africa
2
Slovenia
1
Malaysia
1
Germany
1
Morocco
1
Argentina
1
Peru
1
Israel
1
Taiwan
1
Mexico
1
Ecuador
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic